INTRODUCTION: The burden of MDR-TB is unknown in areas that do not have drug susceptibility testing (DST), but its frequency is expected to be higher in previously treated cases. Where DST is not available the WHO recommended standardized retreatment (Category II) regimen is given to previously treated TB patients OBJECTIVE: To evaluate the frequency and pattern of drug resistance of Mycobacterium tuberculosis isolated from patients with chronic smear positive pulmonary tuberculosis. METHOD: We conducted a retrospective review of mycobacterial cultures and drug susceptibility testing (DST) performed on sputum samples collected, between January 2005 and September 2006, from 40 patients with pulmonary TB who had failed at least one standard retreatment regimen. Clinical data was extracted from patients' case notes. RESULTS: M. tuberculosis was recovered from 28 (70%) of the 40 patients. Of the 28 culture positive cases, 10 (36%) had resistance to at least rifampicin and isoniazid (multi-drug resistant TB), 22 (79%) isolates had resistance to streptomycin and 13 (46%) to ethambutol. Of the patients with a positive culture, only one (3.6%) had a fully susceptible organism. Of the 10 patients with MDR TB, 7 had received two or more retreatment courses. CONCLUSION: The frequency of drug resistant TB was high among patients who failed at least one course of category II therapy. Effective combination regimens based on DST is necessary in patients who remain smear positive on the standardized retreatment regimen.
INTRODUCTION: The burden of MDR-TB is unknown in areas that do not have drug susceptibility testing (DST), but its frequency is expected to be higher in previously treated cases. Where DST is not available the WHO recommended standardized retreatment (Category II) regimen is given to previously treated TBpatients OBJECTIVE: To evaluate the frequency and pattern of drug resistance of Mycobacterium tuberculosis isolated from patients with chronic smear positive pulmonary tuberculosis. METHOD: We conducted a retrospective review of mycobacterial cultures and drug susceptibility testing (DST) performed on sputum samples collected, between January 2005 and September 2006, from 40 patients with pulmonary TB who had failed at least one standard retreatment regimen. Clinical data was extracted from patients' case notes. RESULTS:M. tuberculosis was recovered from 28 (70%) of the 40 patients. Of the 28 culture positive cases, 10 (36%) had resistance to at least rifampicin and isoniazid (multi-drug resistant TB), 22 (79%) isolates had resistance to streptomycin and 13 (46%) to ethambutol. Of the patients with a positive culture, only one (3.6%) had a fully susceptible organism. Of the 10 patients with MDR TB, 7 had received two or more retreatment courses. CONCLUSION: The frequency of drug resistant TB was high among patients who failed at least one course of category II therapy. Effective combination regimens based on DST is necessary in patients who remain smear positive on the standardized retreatment regimen.
Authors: H T W Quy; N T N Lan; M W Borgdorff; J Grosset; P D Linh; L B Tung; D van Soolingen; M Raviglione; N V Cô; J Broekmans Journal: Int J Tuberc Lung Dis Date: 2003-07 Impact factor: 2.373
Authors: Matteo Zignol; Mehran S Hosseini; Abigail Wright; Catharina Lambregts-van Weezenbeek; Paul Nunn; Catherine J Watt; Brian G Williams; Christopher Dye Journal: J Infect Dis Date: 2006-07-12 Impact factor: 5.226
Authors: Vivian Kawai; Giselle Soto; Robert H Gilman; Christian T Bautista; Luz Caviedes; Luz Huaroto; Eduardo Ticona; Jaime Ortiz; Marco Tovar; Victor Chavez; Richard Rodriguez; A Roderick Escombe; Carlton A Evans Journal: Am J Trop Med Hyg Date: 2006-12 Impact factor: 2.345
Authors: G Canetti; W Fox; A Khomenko; H T Mahler; N K Menon; D A Mitchison; N Rist; N A Smelev Journal: Bull World Health Organ Date: 1969 Impact factor: 9.408
Authors: M A Espinal; S J Kim; P G Suarez; K M Kam; A G Khomenko; G B Migliori; J Baéz; A Kochi; C Dye; M C Raviglione Journal: JAMA Date: 2000-05-17 Impact factor: 56.272
Authors: Pedro G Suárez; Katherine Floyd; Jaime Portocarrero; Edith Alarcón; Elisabetta Rapiti; Gilbert Ramos; Cesar Bonilla; Ivan Sabogal; Isabel Aranda; Christopher Dye; Mario Raviglione; Marcos A Espinal Journal: Lancet Date: 2002-06-08 Impact factor: 79.321
Authors: Beth Temple; Irene Ayakaka; Sam Ogwang; Helen Nabanjja; Susan Kayes; Susan Nakubulwa; William Worodria; Jonathan Levin; Moses Joloba; Alphonse Okwera; Kathleen D Eisenach; Ruth McNerney; Alison M Elliott; Peter G Smith; Roy D Mugerwa; Jerrold J Ellner; Edward C Jones-López Journal: Clin Infect Dis Date: 2008-11-01 Impact factor: 9.079
Authors: Ellis Owusu-Dabo; Ohene Adjei; Christian G Meyer; Rolf D Horstmann; Anthony Enimil; Thomas F Kruppa; Frank Bonsu; Edmund N L Browne; Margaret Amanua Chinbuah; Ivy Osei; John Gyapong; Christof Berberich; Tanja Kubica; Stefan Niemann; Sabine Ruesch-Gerdes Journal: Emerg Infect Dis Date: 2006-07 Impact factor: 6.883
Authors: Victoria Panford; Emmanuel Kumah; Collins Kokuro; Prince Owusu Adoma; Michael Afari Baidoo; Adam Fusheini; Samuel Egyakwa Ankomah; Samuel Kofi Agyei; Peter Agyei-Baffour Journal: BMJ Open Date: 2022-07-05 Impact factor: 3.006
Authors: Stephen Osei-Wusu; Michael Amo Omari; Adwoa Asante-Poku; Isaac Darko Otchere; Prince Asare; Audrey Forson; Jacob Otu; Martin Antonio; Dorothy Yeboah-Manu Journal: Infect Drug Resist Date: 2018-02-22 Impact factor: 4.003
Authors: Benjamin D Thumamo Pokam; Dorothy Yeboah-Manu; Daniel Amiteye; Prince Asare; Prisca Wabo Guemdjom; Nchawa Yangkam Yhiler; Samuel Nii Azumah Morton; Stephen Ofori-Yirenkyi; Roger Laryea; Roger Tagoe; Anne Ebri Asuquo Journal: Heliyon Date: 2021-10-09
Authors: Audrey Forson; Awewura Kwara; Samuel Kudzawu; Michael Omari; Jacob Otu; Florian Gehre; Bouke de Jong; Martin Antonio Journal: BMC Infect Dis Date: 2018-04-02 Impact factor: 3.090